David Michael Nanus, M.D.
Dr. Nanus is an internationally recognized leader in the treatment and care of patients with genitourinary (GU) cancers, including cancers of the prostate, kidney, bladder and testes. He is actively involved in clinical, translational and basic research in GU malignancies, serving as principle or co-investigator on a variety of clinical research trials that incorporate novel targeted therapies for his patients. Since 2004, Dr. Nanus who is The Mark W. Pasmantier Professor of Hematology and Oncology in Medicine, has served as Chief of the Division of Hematology and Medical Oncology at Weill Cornell Medical College. He is the recipient of numerous awards including membership in the American Society for Clinical Investigation and the American Association of Physicians.
Dr. Nanus is a graduate of the University of Illinois and the Chicago Medical School. After completing clinical training in Medicine at Albert Einstein and Medical Oncology at Memorial Sloan Kettering Cancer Center, and research training at the Sloan Kettering Institute, he was invited to join the faculty at Memorial Sloan Kettering Cancer Center in 1989. Developing a program in GU cancer, he made several important contributions to clinical and basic research in kidney and prostate cancer. He was recruited to the full-time faculty of Weill Cornell Medical College in 1998.
At Weill Cornell, Dr. Nanus helped develop the Genitourinary Oncology Research Program focused on understanding the events that contribute to the progression of urologic cancers, and on developing new and more effective therapies to treat advanced prostate, kidney and bladder cancer. He was the first Weill Cornell faculty member to obtain a Mid-Career Development Award (K24) from the National Institutes of Health, in support of fostering faculty development and patient-oriented clinical and translational research in the Genitourinary Oncology program. As Director of the Genitourinary Oncology Research Laboratory, he leads a unique interdepartmental team of world class clinical researchers seeking to translate research on the molecular basis of GU cancers into improved cancer treatment.
Insurance Plans Accepted
The following represents most of the managed care plans accepted by this physician. If your insurance carrier does not appear here please feel free to contact this physician or this physician's practice as they may have individual contracts not included on this site.
- AETNA [HMO]
- AETNA [PPO]
- AETNA [Medicare]
- Aetna - Weill Cornell [POS]
- Affinity Health Plan
- Empire Blue Cross/Blue Shield [PPO]
- Empire Blue Cross/Blue Shield [EPO]
- Empire Blue Cross/Blue Shield [Mediblue (Senior)]
- Empire Blue Cross/Blue Shield [HMO]
- Fidelis Care
- GHI [CBP]
- Health First
- Health Insurance Plan of NY (HIP)
- Health Insurance Plan of NY (HIP) [Medicare]
- Health Insurance Plan of NY (HIP) [Medicaid]
- Health Plus - Amerigroup
- Medicare [Medicare]
- Oxford Health Plans [Medicare Advantage]
- Oxford Health Plans [Liberty]
- Oxford Health Plans [Freedom]
- Rockefeller University - CoreSource
- United Empire
- United Health Care [Medicare]
- United Health Care [Community Plan]
- United Health Care
Selected from over 150 Publications
Jeske S, Tagawa ST, Olowokure O, Selzer J, Giannakakou P, Nanus DM. Carboplatin plus paclitaxel therapy after docetaxel in men with metastatic castrate resistant prostate cancer.Urol Oncology 2010, in press.
David KA, Mongan NP, Smith C, Gudas LJ, Nanus DM. Phase I trial of ATRA-IV and Depakote in patients with advanced solid tumor malignancies. Cancer Biol Therapy 2010, in press.
Nanus DM and Milowsky MI. Genitourinary Cancers in ASCO-SEP Medical Oncology Self-Evaluation Program Version II, Moore A, ed, American Society of Clinical Oncology 2010, in press.
Tagawa ST, Milowsky MI, Jeske S, Mazumdar M, Kung S, Sung M, Lehrer D, Matulich D, Selzer J, Wright JJ, Nanus DM. A phase I trial of sorafenib plus gemcitabine and capecitabine for patients with advanced renal cell carcinoma (New York Cancer Consortium trial NCI 6981). Am J Clin Onc 2010;116:1075-83.
Gleghorn JP, Pratt ED, Denning D, Liu H, Bander NH, Tagawa ST, Nanus DM, Giannakakou PA, Kirby BJ. Capture of circulating tumor cells from whole blood of prostate cancer patients using geometrically-enhanced differential immunocapture (GEDI) and a prostate specific antibody. Lab Chip 2010;10:27-9.
Tagawa ST, Patel-Beltran H, Vallabhajosula S, Goldsmith S, Osborne J, Matulich D, Petrillo K, Parmar S, Selzer J, Nanus DM, Bander NH. Anti-prostate membrane specific antigen-based radioimmunotherapy for prostate cancer. Cancer 2009;116:1075-83.
Milowsky MI, Nanus DM, Maluf FC, Mironov S, Shi W, Iasonos A, Riches J, Regazzi A, Bajorin DF. Final results of sequential doxorubicin/gemcitabine (AG) and ifosfamide, paclitaxel, and cisplatin (ITP) chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium. J Clin Onc 2009;27:4062-7.
Jeske S, Del Pizzo JJ, Nanus DM. Kidney Cancer in Atlas of Cancer, Markman M, ed, Lippincott Williams and Wilkins, Philadelphia, 2008.
Dawson NA, Halabi S, Ou SS, Biggs DD, Kessinger A, Vogelzang N, Clamon GH, Nanus DM, Kelly WK, Small EJ. A phase II study of estramustine, docetaxel, and exisulind in Patients with hormone- refractory prostate cancer: Results of cancer and leukemia group B trial 90004. Clin Genitourin Cancer. 2008;6:110-6.
Boorjian SA, Milowsky MI, Kaplan J, Albert M, Rosario C, Coll DM, Mongan NP, Shelton G, Petrylak D, Gudas LJ, Nanus DM. Phase I/II clinical trial of interferon alpha 2b and weekly liposome-encapsulated all-trans retinoic acid in patients with advanced renal cell carcinoma J Immunother 2007;30:655-662.
David KA, Milowsky MI, Ritchey J, Carroll PR, Nanus DM. Low incidence of perioperative chemotherapy in stage III bladder cancer (1998-2003): A report from the National Cancer Data Base. J Urol 2007;178:451-4.
Nanus DM and Milowsky MI. Genitourinary Cancers in ASCO-SEP Medical Oncology Self-Evaluation Program, Moore A, ed, American Society of Clinical Oncology 2007; 205-238.
Horiguchi A, Zheng R, Goodman OB, Shen R, Guan H, Hersh LB, Nanus DM. Lentiviral vector neutral endopeptidase gene transfer suppresses prostate cancer tumor growth. Cancer Gene Therapy 2007;14:583-9.
Hussain M, MacVicar GR, Petrylak D, Dunn R, Vaishampayan U, Lara, Jr PN, Chatta G, Nanus DM, Glode LM, Trump D, Chen H, Smith DC. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced Her-2/neu positive urothelial carcinoma: Results of a multi-center phase II NCI trial. J Clin Onc 2007;25:2218-24..
Tewari A, Divine G, Chang P, Shemtov MM, Milowsky M, Nanus D, Menon M. Long-term survival in men with high grade prostate cancer: a comparison between conservative treatment, radiation therapy and radical prostatectomy--a propensity scoring approach. J Urol. 2007;177:911-5
Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ, Ross JS, Bander NH. Vascular targeted therapy with anti-PSMA monoclonal antibody J591 in patients with advanced solid tumor malignancies, J Clin Onc 2007;25:540-7
David KA, Milowsky MI, Nanus DM. Chemotherapy for non-clear-cell renal cell carcinoma. Clin Genitourin Cancer 2006;4:263-8.
Bander NH, Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Onc 2005;23:4591-601.
Nanus DM, Garino A, Milowsky MI, Larkin M, Dutcher JP. Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma. Cancer 2004;101:1545-1551.
Sumitomo M, Iwase A, Navarro D, Zheng R, Kaminetzky D, Shen R, Georgescu M-M, Nanus DM. Synergy in tumor suppression by direct interaction of neutral endopeptidase with PTEN. Cancer Cell 2004;5:67-78.
Nanus DM, Milowsky MI, Kostakoglu L, Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, Bander NH. Clinical utility of monoclonal antibody HuJ591 therapy: Targeting prostate specific membrane antigen (PSMA). J Urol 2003;170:S84-S89.
Milowsky MI, Rosmarin AS, Tickoo SK, Papanicolaou NI, Nanus DM. Active chemotherapy for collecting duct carcinoma of the kidney: Case report and review of the literature. Cancer 2002:94;111-116.
Papandreou CN, Usmani B, Geng Y, Bogenrieder T, Freeman R, Wilk S, Finstad CL, Reuter VE, Powell CT, Scheinberg D, Magill C, Scher HI, Albino AP, Nanus DM. Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression. Nature Med 1998;4;50-57.
Motzer RJ, Bander NH, Nanus DM. Renal cell carcinoma. N Engl J Med 1996;335:865-875.
Honors and Awards
1982 Dr. John J. Sheinin Research Award for originality and creativity in a research project, University of Health Sciences/Chicago Medical School
1986 National Research Service Award, Cancer Chemotherapy Training Grant Memorial Sloan-Kettering Cancer Center
1988 American Society of Clinical Oncology Young Investigators Award for Cancer Research
1988 American Philosophical Society Daland Fellowship for research in clinical medicine
1990 National Kidney Foundation Young Investigator Grant Award
1991 American Cancer Society Career Development Award
1995-2000 Grant Award from the Association for the Cure of Cancer of the Prostate (CaP CURE)
1998-2010 Best Doctor, Best Doctors in America
2000 Mid-Career Development Award, National Institutes of Health
2001 Member, American Society for Clinical Investigation (ASCI)
2001 Michael Wolk Heart Foundation Department of Medicine Investigator Award, Weill Cornell Medical College
2004 Semi-Finalist, Doris Duke Charitable Foundation Distinguished Clinical Scientist Award
2005 Member, American Association of Physicians (AAP)
2010 2010 Gold DOC Award for sensitivity, kindness and compassion in the practice of medicine, The Arnold P. Gold Foundation
- Medical Oncology
- Intestinal Cancer
- Prostate Cancer
- Bladder Cancer
- Kidney Cancer
Contact and Practices
- Medical Oncology
- Internal Medicine
- M.D., Chicago Medical School, Finch University of Health Sciences, 1982